SCHEMBL4914801

SCHEMBL4914801

CNc1cccc2ccccc12.Cc1nc(Nc2ccc(Br)cc2)sc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
KDM4E B2RXH2 6/20 0.53
DHODH Q02127 4/20 0.53
NPSR1 Q6W5P4 3/20 0.53
NPC1 O15118 7/20 0.49
RAB9A P51151 7/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
POLB P06746 2/20 0.49
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4914862 0.84 MAPT (0.70) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL4914698 0.83 KMT2A (0.53) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL4765972 0.78 NPC1 (0.76) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL4914799 0.77 MAPT (0.53) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL14184653 0.76 MAPT (0.54) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL4923333 0.76 MAPT (0.51) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL4923337 0.75 MAPT (0.53) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL27706868 0.74 SMN1; SMN2 (0.76) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL4929895 0.74 SCD (0.64) MAPTKDM4EDHODHNPSR1NPC1
SCHEMBL27716238 0.72 DHODH (0.79) MAPTKDM4EDHODHNPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP disclosed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 MAPT 1729/4885KDM4E 1589/4885DHODH 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.